quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·46d
PRRelease
MBX Biosciences Inc. logo

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

MBX· MBX Biosciences Inc.
Health Care
Original source

Companies

  • MBX
    MBX Biosciences Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$66.00
  • Dec 4UpdateGoldman$18.00
  • Nov 4UpdateTD Cowen-
  • Oct 15UpdateTruist$50.00
  • Aug 15UpdateJefferies$36.00
  • Aug 5UpdateMizuho$38.00

Related

  • PR1d
    MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
  • SEC1d
    SEC Form 144 filed by MBX Biosciences Inc.
  • SEC2d
    SEC Form DEFA14A filed by MBX Biosciences Inc.
  • SEC2d
    SEC Form DEF 14A filed by MBX Biosciences Inc.
  • INSIDER2d
    Amendment: SEC Form 4 filed by Hoerter Steven L.
  • INSIDER2d
    Amendment: SEC Form 4 filed by Hoerter Steven L.
  • PR21d
    MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • SEC29d
    SEC Form 144 filed by MBX Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022